Carl Zeiss Meditec AG expects revenue for fiscal year 2019/20 of approx. EUR 1.3 billion
Jena, Germany | Carl Zeiss Meditec AG
In view of the continuing Covid-19 pandemic and its impact on relevant markets, Carl Zeiss Meditec AG (ISIN: DE0005313704) expects to see a further impact on business development in the remainder of fiscal year 2019/20 compared to previous year.
Assuming a recovery in markets and, in particular, that no significant additional measures to contain the Covid-19 pandemic will impact development, management anticipates revenue of around €1.3bn for fiscal year 2019/20 (previous year €1.459bn).
In the first nine months of fiscal year 2019/20, Carl Zeiss Meditec has achieved revenue of €967.9m (previous year €1,027.6m). This corresponds to a decline of 5.8% vs. the previous year. After adjustment for currency effects1, the decline amounted to 6.9%.
Earnings before interest and taxes (EBIT) amounted to €111.9m after the first nine months of 2019/20 (previous year: €184.2m). Earnings per share (EPS) were €0.77 (previous year: €1.22).
The quarterly statement of the first nine months of fiscal year 2019/20 will be published on August 5, 2020.
Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 4,823 employees worldwide, the Group generated revenue of €2,089.3m in fiscal year 2022/23 (to 30 September).
The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.
For more information visit our website at www.zeiss.com/med
Currency-adjusted revenue growth is determined by calculating sales in the current period using the historical exchange rates of the prior year period.